PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing ...

Understand the key differences between Crohn’s disease and ulcerative colitis, common symptoms, early detection methods and ...

Patients with active ulcerative colitis may be able to reduce symptoms and achieve remission by taking a plant-based treatment combining the herbal compounds curcumin and qingdai, preliminary results ...

Researchers at the University of Michigan Health Rogel Cancer Center discovered a new mechanism for eliminating one of the main side effects of immunotherapy treatment: colitis. Immunotherapy is used ...

Young adults were more likely to report low confidence in knowing which coverage-related questions to ask their insurers, and ...

According to preliminary results announced Thursday, the BMS drug did not beat a placebo measured against the study’s main goal of showing clinical remission in ulcerative colitis, an inflammatory ...

Microscopic colitis is a lifelong condition that causes symptoms such as diarrhea and abdominal pain. It is a type of inflammatory bowel disease (IBD). While there is no cure for microscopic colitis, ...

An experimental monoclonal antibody treatment appears to ease the digestive disorder ulcerative colitis in patients who've failed other medications, a new trial shows. The treatment, tulisokibart, ...

You probably already know this part, but a quick refresher doesn’t hurt. As a form of inflammatory bowel disease (IBD), ulcerative colitis creates inflammation in the gastrointestinal (G.I.) tract.

How Does Tremfya Work for Ulcerative Colitis? Tremfya is a monoclonal antibody that reduces inflammation. The main ingredient in Tremfya is a medicine called guselkumab. This medicine blocks a ...

(MENAFN- EIN Presswire) EINPresswire/ -- According to DataM Intelligence, the ulcerative colitis treatment market size reached US$ 7.60 billion in 2023, increased to US$ 7.98 billion in 2024, and is ...